GNBT Rated BUY After Setting Dividend Record Date Of Nov 5 and Announcing Partnership With Canopy Growth Backed HydRx Farms

New York, NY – October 31, 2018 – Generex Biotechnology Corp (OTCQB: GNBT) stock has been rated a BUY based on candle stick analysis. The rating comes after the company announced a 20:1 for one dividend record date of Monday, November 5th, 2018 with a rapid payment date the next week on November 13th.  Generex became a prominent new player in the cannabis pharmaceutical sector recently when the company  announced a deal with HydRx Farms Ltd. which is more commonly known by its operating name, Scientus Pharma.  Scientus is backed by Canopy Growth (NYSE: CGC).  The BUY rating was issued before the Generex BREAKING NEWS just published this morning on the company’s acquisition of the remaining assets Vento Holding.

Screen Shot 2018-11-02 at 7.17.51 AM.png

 “Our system’s recommendation today is to BUY. The BULLISH ONE WHITE SOLDIER pattern finally received a confirmation because the prices crossed above the confirmation level which was at 9.9500, and our valid average buying price stands now at 10.0150. 

The green light is on and this security is now screaming BUY. It is action time! The bullish pattern that was previously identified is finally confirmed and a BUYsignal is generated. Most probably, it is the right time to participate in bullish fervor. Do not miss this bullish opportunity”

See our previous release on Generex from earlier this week:

Generex Enters $50 Billion Cannabis Pharmaceuticals Sector With Canopy Growth Backed Partner

Learn more about Generex at

DISCLAIMER: (NBT)is a third party publisher and news dissemination service provider. NBT is NOT affiliated in any manner with any company mentioned herein. NBT is news dissemination solutions provider and are NOT a registered broker/dealer/analyst/adviser, holds no investment licenses and may NOT sell, offer to sell or offer to buy any security. NBT's market updates, news alerts and corporate profiles are NOT a solicitation or recommendation to buy, sell or hold securities. The material in this release is intended to be strictly informational and is NEVER to be construed or interpreted as research material. All readers are strongly urged to perform research and due diligence on their own and consult a licensed financial professional before considering any level of investing in stocks. All material included herein is republished content and details which were previously disseminated by the companies mentioned in this release or opinion of the writer. NBT is not liable for any investment decisions by its readers or subscribers. Investors are cautioned that they may lose all or a portion of their investment when investing in stocks. NBT has not been compensated for this release and HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.

Disclaimer/Safe Harbor:

This news release contains forward-looking statements within the meaning of the Securities Litigation Reform Act. The statements reflect the Company's current views with respect to future events that involve risks and uncertainties. Among others, these risks include the expectation that any of the companies mentioned herein will achieve significant sales, the failure to meet schedule or performance requirements of the companies' contracts, the companies' liquidity position, the companies' ability to obtain new contracts, the emergence of competitors with greater financial resources and the impact of competitive pricing. In the light of these uncertainties, the forward-looking events referred to in this release might not occur.